• Contact us
  • Advertise with us
  • Login
Tashi Pharma
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    FDA provides new guidance to further enhance the security of prescription drugs in the U.S. supply chain

    FDA provides new guidance to further enhance the security of prescription drugs in the U.S. supply chain

    FDA Publishes Draft Guidance on Oral Drug Products Administered Via Enteral Feeding Tube

    FDA Publishes Draft Guidance on Oral Drug Products Administered Via Enteral Feeding Tube

    FDA updated its guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19

    FDA updated its guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19

    EU Authority writes to MA holder with regards to Azido impurity in irbesartan

    EU Authority writes to MA holder with regards to Azido impurity in irbesartan

    USFDA publishes guidance for Bispecific Antibody Development Programs

    USFDA publishes guidance for Bispecific Antibody Development Programs

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    FDA provides new guidance to further enhance the security of prescription drugs in the U.S. supply chain

    FDA provides new guidance to further enhance the security of prescription drugs in the U.S. supply chain

    FDA Publishes Draft Guidance on Oral Drug Products Administered Via Enteral Feeding Tube

    FDA Publishes Draft Guidance on Oral Drug Products Administered Via Enteral Feeding Tube

    FDA updated its guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19

    FDA updated its guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19

    EU Authority writes to MA holder with regards to Azido impurity in irbesartan

    EU Authority writes to MA holder with regards to Azido impurity in irbesartan

    USFDA publishes guidance for Bispecific Antibody Development Programs

    USFDA publishes guidance for Bispecific Antibody Development Programs

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
No Result
View All Result
Home Indian Pharma News

COVISHEILD priced at INR 400 for state government & INR 600 for private hospitals

PRN by PRN
April 21, 2021
in Indian Pharma News
7 0
0
COVISHEILD priced at INR 400 for state government & INR 600 for private hospitals
5
SHARES
11
VIEWS

Serum Institute of India has announced price for the vaccine for the upcoming phase III vaccination programme in India

COVISHEILD priced at INR 400 for state government & INR 600 for private hospitals

 

Tags: covidCOVISHEILDPharma NewspharmacyPharmareg NewsSerum Institute of IndiaVaccine
Previous Post

Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following EMA Review

 Next Post

Johnson & Johnson Reports strong growth in First-Quarter of 2021

PRN

PRN

Related Posts

Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Indian Pharma News

Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

by PRN
June 7, 2021
Lupin Launches Digital Asthma Educator platform
Indian Pharma News

Lupin Launches Digital Asthma Educator platform

by PRN
June 7, 2021
An entrepreneur who loves marketing
Indian Pharma News

An entrepreneur who loves marketing

by PRN
June 6, 2021
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg
Indian Pharma News

Glenmark receives ANDA approval for Theophylline ER Tablets, 300 mg and 450 mg & is eligible for 180 days of CGT exclusivity on the 450 mg

by PRN
June 4, 2021
Lupin Launches Authorized Generic Version of Brovana® in the United States
Indian Pharma News

Lupin Launches Authorized Generic Version of Brovana® in the United States

by PRN
June 4, 2021
Next Post
Johnson & Johnson Reports strong growth in First-Quarter of 2021

Johnson & Johnson Reports strong growth in First-Quarter of 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

mneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

June 7, 2021
Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

June 7, 2021
argenx to regain global rights to cusatuzumab

argenx to regain global rights to cusatuzumab

June 7, 2021
U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera

U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft

June 7, 2021
Daiichi Sankyo Submits Application for Additional Indication of Mirogabalin in Japan

Daiichi Sankyo Submits Application for Additional Indication of Mirogabalin in Japan

June 7, 2021

Browse by Category

  • Articles
  • Company Focus
  • EDQM
  • EMA
  • European Commision
  • Global Pharma News
  • Guideline News
  • Health Canada
  • Indian Pharma News
  • Interview
  • Medsafe
  • MHRA
  • SAHPRA
  • US FDA
  • Webinar

Browse by Tags

Abbott Alembic Amgen AstraZeneca bayer Bharat Biotech biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant latest pharma news lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sputnik V Sun pharma Teva usfda Vaccine vertex zydus

Contact us

Address:Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002.
Phone:+91 8511586232, +91 9029066605
Email:author@pharmaregnews.com

Browse by Tag

Abbott Alembic Amgen AstraZeneca bayer Bharat Biotech biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant latest pharma news lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sputnik V Sun pharma Teva usfda Vaccine vertex zydus

Advertise with us

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • bioanalytical
    • Clinical
  • Webinar
  • Contact us
  • Advertise with us
  • Login

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
This site uses cookies: Find out more.